Clinical trials: VTE
Venous Thromboembolism (VTE), Occult Cancer
External Validation of the CLOVER Score for Detecting Occult Cancer in Venous Thromboembolism Patients
This study aims to externally validate the CLOVER score, a machine learning-based predictive model designed to identify patients with venous thromboembolism (VTE) who are at increased risk of having an occult cancer.
- Trial name
- CLOVER (NCT07310693)
- Where
- 12 sites in Spain
- Volunteers
- 500 people
- Sponsor
- Infanta Leonor University Hospital
Pulmonary Embolism Acute, Venous Thromboembolism (VTE)
Bleeding Risk With Apixaban Versus Rivaroxaban in Acute Pulmonary Embolism
This prospective, open-label, randomized controlled trial will compare clinically relevant bleeding during the first three months of treatment with apixaban versus rivaroxaban in adults with acute pulmonary embolism (PE) in a…
- Trial name
- APIX-PE (Apixa (NCT07774273)
- Testing
- Drug: Apixaban, Drug: Rivaroxaban
- Where
- Pakistan
- Volunteers
- 540 people
- Sponsor
- Combined military hospital lahore
Pulmonary Embolism, Deep Vein Thrombosis
The Angel® Catheter Pivotal Clinical Trial
The primary objective of this multicenter, prospective, single arm clinical trial is to evaluate the safety and effectiveness of the Angel® Catheter in subjects at high risk of PE, and with recognized contraindications to…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism, Trauma
- Trial name
- NCT02186223
- Testing
- The Angel® Catheter
- Where
- 21 sites in United States
- Volunteers
- 172 people
- Sponsor
- BiO2 Medical
Thromboembolism, Pregnancy
Pregnancy and Risk of Venous Thromboembolism
The management of venous thromboembolism (VTE) risk in pregnancy still remains a challenge. An individual assessment of the VTE risk is crucial for optimal thromboprophylaxis, but there is no validated tool to help clinicians…
- Trial name
- PRESCOT (NCT03659708)
- Testing
- Lyon-VTE score, recommendations currently available
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Hospices Civils de Lyon
Venous Thromboembolism (VTE), Total Joint Arthroplasty
Efficacy of Aspirin in Preventing Venous Thromboembolism
Efficacy of aspirin and enoxaparin in preventing venous tromboembolism was compared after total knee or hip arthroplasty.
- Conditions
- Venous Thromboembolism (VTE), Total Joint Arthroplasty, Total Hip Arthroplasty (THA)
- Trial name
- NCT06635317
- Testing
- Aspirin, enoxaparin
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
Venous Thromboembolism
Statin Use in Patients With Acute VTE
This is a pilot, randomized, open-labelled study. Eligible patients will be enrolled and randomized 1:1 into "anticoagulation" arm or "anticoagulation plus atorvastatin" arm, with atorvastatin given at 40 mg orally daily for 3…
- Trial name
- NCT02331095
- Testing
- Atorvastatin, Anticoagulation Therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Ohio State University
Venous Thromboembolic Disease, Post Thrombotic Syndrome
Long-term Outcome After Edoxaban Versus Vitamin K Antagonists for Acute VTE
The HOKUSAI post VTE study contains of two different research questions; one on the long term outcomes of deep vein thrombosis and one on the long term effects of pulmonary embolism, post thrombotic syndrome (PTS) and chronic…
- Conditions
- Venous Thromboembolic Disease, Post Thrombotic Syndrome, Chronic Thromboembolic Pulmonary Hypertension, Quality of Life
- Trial name
- HOKUSAIpostVTE (NCT04007653)
- Testing
- Observation
- Where
- Netherlands
- Volunteers
- 1,200 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Venous Thromboembolism, Pulmonary Embolus
Multicenter Registry for Comparative Effectiveness Analysis of Venous Thromboembolism in Trauma Patients
Venous thromboembolism (VTE) remains a leading cause of death in trauma patients. Based on the EAST Management Guidelines for the prevention of VTE in trauma patients, a number of research questions could be addressed by a…
- Conditions
- Venous Thromboembolism, Pulmonary Embolus, Deep Vein Thrombosis
- Trial name
- CLOTT (NCT01890044)
- Where
- United States
- Sponsor
- Scripps Health
Venous Thrombosis (Disorder)
Patient Education Bundle vs. Nurses Feedback and Coaching to Prevent Missed Doses of VTE Prophylaxis
VTE associated harm is underappreciated among hospitalized patients and may be associated with missed doses of VTE prophylaxis medications.
- Trial name
- ENACT (NCT03367364)
- Testing
- Patient education bundle (PEB),, Nurse feedback and coaching (NFC)
- Where
- United States
- Volunteers
- 9,657 people
- Sponsor
- Johns Hopkins University
Thromboembolism
Evaluation of the Risk of VTE Among Patients Hospitalized in Non-surgical Departments
Patients hospitalized in internal wards are at risk for VTE. The current guidelines recommend the use of thromboprophylaxis for 7-10 days among patients who are at increased risk for VTE.
- Trial name
- NCT03073915
- Volunteers
- 4,000 people
- Sponsor
- Hadassah Medical Organization
Neoplasms, Venous Thromboembolism
National Evaluation of the Adherence to Recommendations of Venous Thrombo Embolism Treatment in Cancer Patients
Treatment of venous thromboembolism in cancer patients is specific and has been validated in trials that favor the use of LMWH (Low Molecular Weight Heparin) instead of VKA (Vitamin K Antagonist) treatment during 6 months.
- Trial name
- CARMEN (NCT01362933)
- Testing
- VTE treatment in cancer patient description
- Where
- 49 sites in France
- Volunteers
- 502 people
- Sponsor
- Floralis
Venous Thromboembolism
EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization
Primary objective: To demonstrate the superiority of extended VTE prophylaxis with enoxaparin 40mg sc qd for 28 ± 4 days, compared to placebo, both following 10 ± 4 days of initial treatment with enoxaparin 40mg sc qd Secondary…
- Trial name
- NCT00077753
- Testing
- enoxaparin sodium
- Where
- 20 sites in United States, Argentina and 18 more
- Volunteers
- 4,726 people
- Sponsor
- Sanofi
Venous Thromboses
Intermittent Pneumatic Compression of the Upper Extremity for Post-Operative VTE Prophylaxis
Venous thromboembolism (VTE) is an important cause of morbidity and mortality following surgery.A combination of chemical and mechanical prophylaxis using lower extremity compression devices (CD) is recommended in patients who…
- Trial name
- NCT04341272
- Testing
- Intermittent Pneumatic Compression Device (FDA approved)
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Baltimore VA Medical Center
Venous Thromboembolism (VTE), Chronic Thromboembolic Pulmonary Hypertension
Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance
PERSEUS is an academic, investigator-initiated, multicenter observational registry of adults with acute pulmonary embolism (PE), promoted by Azienda Ospedaliero-Universitaria Careggi (Florence, Italy).
- Conditions
- Venous Thromboembolism (VTE), Chronic Thromboembolic Pulmonary Hypertension, Right Ventricular Dysfunction, Pulmonary Embolism (PE)
- Trial name
- PERSEUS (NCT07855679)
- Testing
- Routine clinical care (no study intervention)
- Where
- 16 sites in Italy, Poland and 1 more
- Volunteers
- 5,000 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Venous Thromboembolism, Cancer
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
In this study the investigators will determine the safety and effectiveness of Tinzaparin in preventing blood clots for up to 12 months of treatment.
- Trial name
- NCT00981903
- Testing
- Tinzaparin sodium
- Where
- 2 sites in United States
- Volunteers
- 131 people
- Sponsor
- University of Southern California
Circadian Variation in Anti-Factor Xa (Anti-FXa) Activity
Circadian Variation of Anti-Factor Xa in Hospitalized Trauma Patients
The purpose of this study is to determine whether a circadian rhythm exists in anti-FXa levels and AT3 activity in hospitalized trauma patients receiving low-molecular-weight heparin (LMWH) chemoprophylaxis
- Trial name
- NCT07856641
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The University of Texas Health Science Center, Houston